ACD856 (NeuroRestore) is a revolutionary molecule: a positive allosteric modulator (PAM) of Trk receptors. No other known synthetic or natural molecule does this.
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
Transaction en cours
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.